Prostate cancer immunotherapy significantly prolongs survival in men with advanced prostate cancer

Apr 29, 2009

Sipuleucel-T (Provenge), an experimental immunotherapy improved survival in men with metastatic disease, according to new results to be presented April 28 at the American Urological Association (AUA) Annual Scientific Meeting in Chicago. These data from the Phase 3 Immunotherapy for Prostate AdenoCarcinoma Treatment (IMPACT) study were presented during the meeting's Late Breaking Science Forum.

Compared to placebo, sipuleucel-T extended median survival by 4.1 months and improved three-year survival by 38 percent. Sipuleucel-T successfully exceeded the pre-specified level of statistical significance defined by the study's design and reduced the overall risk of death by 22.5 percent compared to placebo (p-value=0.032). More than 500 patients were enrolled in the IMPACT trial, a multi-center, randomized, double-blind, placebo-controlled study evaluating men with asymptomatic or minimally symptomatic, metastatic, androgen-independent . The primary endpoint was overall survival.

Researchers are encouraged by the findings, citing an impressive effect on long-term survival for patients, compared to placebo.

"The ability to boost survival for patients is the gold standard endpoint in prostate cancer clinical trials," said AUA spokesperson Ira D. Sharlip, MD. "The ability to give these both increased survival and possibly, improved quality of life, is very important."

Sipuleucel-T is an investigational therapy for men with androgen-independent prostate cancer. It is an active cellular immunotherapy designed to use live to boost a patient's to elicit a long-lasting response against cancer.

Source: American Urological Association

Explore further: Solving cancer's secrets

add to favorites email to friend print save as pdf

Related Stories

Prostate cancer vaccines more effective with hormone therapy

Jul 10, 2008

Among patients with castration-resistant prostate cancer, the addition of hormone therapy following vaccine treatment improved overall survival compared with either treatment alone or when the vaccine followed hormone treatment, ...

Recommended for you

Solving cancer's secrets

3 minutes ago

Some fathers play ball with their sons. Or take them fishing. Chuck Perou's father took his son to his pathology lab to show him how a pathologist conducts tests and runs experiments. Perou, a nature junky ...

Cancer stem cells linked to drug resistance

19 hours ago

Most drugs used to treat lung, breast and pancreatic cancers also promote drug-resistance and ultimately spur tumor growth. Researchers at the University of California, San Diego School of Medicine have discovered ...

User comments : 0

More news stories

Scientists make critical end-stage liver discovery

(Medical Xpress)—A team of researchers in the University of Arizona's College of Pharmacy has discovered a molecular pathway that could be key to creating new therapeutics that would slow or even reverse ...

Atom probe assisted dating of oldest piece of earth

(Phys.org) —It's a scientific axiom: big claims require extra-solid evidence. So there were skeptics in 2001 when University of Wisconsin-Madison geoscience professor John Valley dated an ancient crystal ...